2144751-78-8

CTX-712 is an orally effective CLK 2 inhibitor, with an IC50 of 1.4 nM, showing anti-tumor activity[1][2].

CTX-712 is a potent inhibitor of cdc2-like kinase (CLK). CTX-712 inhibits CLK kinase activity, and thus inhibits cancer survival and cancer cell growth. CTX-712 has the potential for the research of cancer disease (extracted from patent JPWO2017188374A1, compound 286)[1].

CLK2: 1.4 nM (IC₅₀)

Store at -20°C

[1]. Fused heterocyclic compounds. Patent JPWO2017188374A1.